Malaria during pregnancy Infections and Infestations Plasmodium falciparum malaria
Conditions
Interventions
Through an open label block randomisation (block size of 20)
women were assigned to receive one of the treatment regimens (two or three doses of SP). One treatment dose was 1500 mg of sulfadoxine and 75 mg of pyrimethamine. Sequence of dosing admistration was a
Sponsors
National Direction of Health (Mali)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 14 to 45 years, female pregnant women 2. Gestational age between 16 and 24 weeks 3. Provide consent form 4. Not having chronic disease 5. Willing to terminate the study and follow study conditions
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Placental malaria. Placental blood was collected from the maternal side of the placenta (after cleaning using filter paper before cutting with cleaned lancet) for thick blood smear for parasitaemia detection. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Low birth weight. Gestational age at delivery was assessed using the Ballard score, and infants were weighed using a digital scale within 24 hours of delivery to measure the incidence of low birth weight. 2. Maternal anaemia. Following delivery, haemoglobin concentration was measured by HemoCue® (Hemocue 201: Anglholm, Sweden) and peripheral parasitaemia was assessed by peripheral blood smear. | — |
Countries
Mali
Outcome results
None listed